Of note, roneparstat inhibited ERBB4 activation as well as HB-EGF-induced Matrigel invasion (Figure 3C) also in the CME-1 synovial sarcoma cell line, which harbors a constitutively active receptor (Supplementary Figure S1). Here, ERBB4 is linked to synovial sarcoma.